Immunoassays (ELISA) of Urokinase-type Plasminogen Activator (uPA): Report of an EORTC/BIOMED-1 Workshop

By Benraad T.J.   Geurts-Moespot J.   Grondahl-Hansen J.   Schmitt M.   Heuvel J.J.T.M.   de Witte J.H.   Foekens J.A.   Leake R.E.   Brunner N.   Sweep C.G.J.  

European Journal of Cancer, Vol. 32, Iss. 8, 1996-07 ,pp. : 1371-1381

Elsevier

Access to resources Recommend Favorite

Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions

By Daneri-Navarro A.   Macias-Lopez G.   Oceguera-Villanueva A.   Del Toro-Arreola S.   Bravo-Cuellar A.   Perez-Montfort R.   Orbach-Arbouys S.  

European Journal of Cancer, Vol. 34, Iss. 4, 1998-03 ,pp. : 566-569

Elsevier

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface

By Gerspach Jeannette   Németh Julia   Münkel Sabine   Wajant Harald   Pfizenmaier Klaus  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 12, 2006-12 ,pp. : 1590-1600

Springer Publishing Company

Access to resources Recommend Favorite

Celecoxib Inhibits Urokinase-Type Plasminogen Activator (uPA) Production in MDA-MB-231 Breast Cancer Cells

By Andrews Heather   Habibi Golerah   Kucab Jill   Dunn Sandra  

Breast Cancer Research and Treatment, Vol. 94, Iss. 1, 2005-11 ,pp. : 47-52

Springer Publishing Company

Access to resources Recommend Favorite